Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
A single center, pilot trial using tamsulosin and solifenacin in 10 men with symptomatic
lower urinary tract symptoms (LUTS). Subjects will be evaluated at baseline, 1, 2, and 3
months for urinary NGF, urine creatinine, NGF/CR ratio and patient reported outcomes through
questionnaires.
Phase:
Phase 4
Details
Lead Sponsor:
The Methodist Hospital System Timothy Boone, MD, PhD